Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(01): 021-024
DOI: 10.1055/s-0041-1729734
Courting Controversy

Can Cancer Survivors Donate Convalescent Plasma for the Treatment of COVID-19?

Ajit Venniyoor
1   National Oncology Centre, The Royal Hospital, Muscat, Sultanate of Oman
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Case Vignette

SS is a 50-year-old female treated for stage III colon cancer in 2010 and on a 6-monthly follow-up. She missed her scheduled review in July 2020 and informed that she could not come on for her appointment due to coronavirus disease 2019 (COVID-19) infection, which affected her whole family, all of whom had mild symptoms and recovered uneventfully. I suggested that she could now donate convalescent plasma (CP) for the treatment of seriously ill COVID-19 patients, and she was immediately interested. I advised her to go to the hospital’s blood transfusion center and volunteer. Later, I had a call from the transfusion medical officer asking me to clarify whether cancer survivors can donate blood or blood products.



Publication History

Article published online:
18 May 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Morens DM, Daszak P, Markel H, Taubenberger JK. Pandemic COVID-19 joins history’s pandemic legion. MBio 2020; 11 (03) e00812-e00820
    CrossrefPubMedGoogle Scholar
  • 2 Kulkarni P, Dhanushkodi M. Novel coronavirus severe acute respiratory syndrome-coronavirus 2 (coronavirus disease 2019): we shall overcome!. Indian J Med Paediatr Oncol 2020; 41: 110-113
    Article in Thieme ConnectGoogle Scholar
  • 3 MacIntyre CR, Wang Q. Physical distancing, face masks, and eye protection for prevention of COVID-19. Lancet 2020; 395 (10/242) 1950-1951
    CrossrefPubMedGoogle Scholar
  • 4 Horby P, Lim WS, Emberson JR. et al. . RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med 2020; NEJMoa2021436 DOI: 10.1056/ NEJMoa2021436.
    CrossrefPubMedGoogle Scholar
  • 5 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med 2020; 383: 992-994 DOI: 10.1056/NEJMoa2007764.
    CrossrefPubMedGoogle Scholar
  • 6 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130 (06) 2757-2765
    CrossrefPubMedGoogle Scholar
  • 7 Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol 2020; 92 (09) 1475-1483 [doi: 10.1002/jmv.25961]
    CrossrefPubMedGoogle Scholar
  • 8 Piechotta V, Chai KL, Valk SJ. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020; 7: CD013600
    PubMedGoogle Scholar
  • 9 prpt. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020/prpt
  • 10 Long QX, Liu BZ, Deng HJ. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26 (06) 845-848
    CrossrefPubMedGoogle Scholar
  • 11 Anonymous. Clinical Management Protocol: COVID-19. Ministry of Health and Family Welfare Guidelines. Available from:https://www.mohfw.gov.in/pdf/ Clinical ManagementProtocolforCOVID19.pdf. Accessed April 13, 2021
  • 12 Ibarrondo FJ, Fulcher JA, Goodman-Meza D. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med 2020; 383 (11) 1085-1087
    CrossrefPubMedGoogle Scholar
  • 13 prpt . Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv 2020. pre-print. [doi: 10.1101/2020.07.09.20148429]./prpt
  • 14 Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020; 6 (07) 1108-1110
    CrossrefPubMedGoogle Scholar
  • 15 Dai M, Liu D, Liu M. et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multi center study during the COVID-19 outbreak. Cancer Discov 2020; 10 (06) 783-791
    CrossrefPubMedGoogle Scholar
  • 16 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
    CrossrefPubMedGoogle Scholar
  • 17 Pathak R, Chitkara G, Kulkarni P, Bhattacharyya GS, Gupta S, Bajpai J. Tale of constant adaptation, revision, and change of cancer therapy during the ongoing COVID crisis: adapting to cope and win. Indian J Med Paediatr Oncol 2020; 41: 103-109
    Article in Thieme ConnectGoogle Scholar
  • 18 van Dam PA, Huizing M, Mestach G. et al. SARS-CoV-2 and cancer: are they really partners in crime?. Cancer Treat Rev 2020; 89: 102068
    CrossrefPubMedGoogle Scholar
  • 19 Lee LY, Cazier JB, Angelis V. et al. UK Coronavirus Monitoring Project Team. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395 (10/241) 1919-1926
    CrossrefPubMedGoogle Scholar
  • 20 prpt . Robilotti EV, Babady NE, Mead PA, et al. Determinants of severity in cancer patients with COVID-19 illness. medRxiv 2020. pre-print [doi: 10.1101/2020.05.04.20086322]./prpt
  • 21 Montopoli M, Zumerle S, Vettor R. et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol 2020; 31 (08) 1040-1045
    CrossrefPubMedGoogle Scholar
  • 22 Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. Transplantation 2012; 94 (12) 1200-1207
    CrossrefPubMedGoogle Scholar
  • 23 Yang H, Lee J, Seed CR, Keller AJ. Can blood transfusion transmit cancer? A literature review. Transfus Med Rev 2010; 24 (03) 235-243
    CrossrefPubMedGoogle Scholar
  • 24 Goel R, Tobian AA, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood 2019; 133 (17) 1831-1839
    CrossrefPubMedGoogle Scholar
  • 25 Edgren G, Hjalgrim H, Reilly M. et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet 2007; 369 (95/74) 1724-1730
    CrossrefPubMedGoogle Scholar
  • 26 Anonymous. Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee Donor Selection Guidelines. Available from: https:// www.transfusionguidelines.org/dsg/wb/guidelines/ma006-malignancy. Accessed April 13, 2021
  • 27 Anonymous. American Red Cross. Frequently Asked Questions. Available from: https://www.redcrossblood.org/faq. html#eligibility-medicalconditions. Accessed April 13, 2021
  • 28 Anonymous. National Blood Transfusion Council. Guidelines for Blood Donor Selection and Donor Referrals. Available from: http://nbtc.naco.gov.in/page/policies_guidelines/. Accessed April 13, 2021
  • 29 Miller KD, Nogueira L, Mariotto AB. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69 (05) 363-385
    CrossrefPubMedGoogle Scholar
  • 30 Rubin LG, Levin MJ, Ljungman P. et al. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (03) e44-e100
    CrossrefPubMedGoogle Scholar
  • 31 Shah MK, Kamboj M. Immunizing cancer patients: which patients? Which vaccines? When to give?. Oncology (Williston Park) 2018; 32 (05) 254-258, C3
    Google Scholar
  • 32 Nazi I, Kelton JG, Larché M. et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013; 122 (11) 1946-1953
    CrossrefPubMedGoogle Scholar
  • 33 Frederiksen B, Specht L, Henrichsen J, Pedersen FK, Pedersen-Bjergaard J. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin’s disease. Eur J Haematol 1989; 43 (01) 45-49
    CrossrefPubMedGoogle Scholar
  • 34 Choi W, Kim JG, Beom SH. et al. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a randomized controlled trial. Cancer Res Treat 2020; 52 (01) 246-253
    CrossrefPubMedGoogle Scholar
  • 35 Nordøy T, Aaberge IS, Husebekk A. et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19 (02) 71-78
    CrossrefPubMedGoogle Scholar